LivaNova PLC (LIVN)
NASDAQ: LIVN · IEX Real-Time Price · USD
53.61
+0.16 (0.30%)
Jul 26, 2024, 4:00 PM EDT - Market closed
LivaNova Revenue
LivaNova had revenue of $294.91M in the quarter ending March 31, 2024, with 11.96% growth. This brings the company's revenue in the last twelve months to $1.19B, up 13.40% year-over-year. In the year 2023, LivaNova had annual revenue of $1.15B with 12.89% growth.
Revenue (ttm)
$1.19B
Revenue Growth
+13.40%
P/S Ratio
2.45
Revenue / Employee
$408,634
Employees
2,900
Market Cap
2.90B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1.15B | 131.74M | 12.89% |
Dec 31, 2022 | 1.02B | -13.56M | -1.31% |
Dec 31, 2021 | 1.04B | 101.12M | 10.82% |
Dec 31, 2020 | 934.24M | -149.93M | -13.83% |
Dec 31, 2019 | 1.08B | -22.79M | -2.06% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Apr 24, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
agilon health | 4.78B |
Envista Holdings | 2.56B |
ICU Medical | 2.26B |
ACADIA Pharmaceuticals | 813.81M |
Tandem Diabetes Care | 770.01M |
Amicus Therapeutics | 423.49M |
Rhythm Pharmaceuticals | 91.93M |
LIVN News
- 8 hours ago - SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of LivaNova PLC - LIVN - GlobeNewsWire
- 2 days ago - SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of LivaNova PLC - LIVN - PRNewsWire
- 12 days ago - SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of LivaNova PLC - LIVN - Accesswire
- 4 weeks ago - Federman & Sherwood Investigates LivaNova USA, Inc. for Data Breach - Business Wire
- 5 weeks ago - LivaNova to Announce Second-Quarter 2024 Results - Business Wire
- 7 weeks ago - LivaNova Provides Update on RECOVER Clinical Study Evaluating VNS Therapy for Treatment-Resistant Depression in Unipolar Patients - Business Wire
- 2 months ago - LivaNova to Present at the Goldman Sachs Healthcare Conference - Business Wire
- 3 months ago - LivaNova Reports First-Quarter 2024 Results - Business Wire